Developer docs
API playgroundTry for free, no card

Search company profiles

Roxall Medizin

Full company profile

uuid000s1g7

Namestring
Roxall Medizin
Legal namestring
ROXALL Group
Websiteurl
roxall.com
Company typeenum
Private
Founded yearint
1994
Descriptiontext

ROXALL Group is a privately held specialty pharmaceutical company focused on allergology and immunotherapy, claiming approximately 30 years of innovation in the field (founded circa 1994). The company develops and distributes prescription allergy immunotherapy treatments, positioning immunotherapy as its flagship offering, and serves allergologists, immunology specialists, pharmacies, wholesalers, and patients across six European countries: Spain, Germany, Austria, Italy, Portugal, and Turkey. Its operational headquarters is located in the Zamudio Technology Park in Bizkaia, Spain.

The company's product portfolio is centered on its allergy immunotherapy treatments, with a secondary digital offering in RoxVac—a pharmacy-facing real-time order tracking and management platform launched in 2023 that allows pharmacies and wholesalers to register vaccine orders, monitor delivery status, and access product and batch information. ROXALL also maintains a gated professional area portal for healthcare providers, which includes a portfolio, an events calendar, and a Hymenoptera Blog, alongside a patient-facing section covering allergy education and order tracking.

ROXALL's go-to-market relies on direct sales representatives engaging allergologists and immunology specialists, supported by country-specific localized websites in each European market, professional events and conferences, and distribution through pharmacies and wholesalers. The company emphasizes R&D as part of its identity and has a pharmacovigilance and ethical channel consistent with regulated pharmaceutical operations. No funding rounds, M&A activity, partnerships, or revenue figures are disclosed in the available data.

Short descriptiontext

ROXALL Group is a private specialty pharmaceutical company developing and distributing prescription allergy immunotherapy treatments across six European countries, serving allergologists, pharmacies, wholesalers, and patients via direct sales and its RoxVac order-tracking platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOststeinbek, Germany
HQ citystring
Oststeinbek
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allergy immunotherapy, specialty pharmaceuticals, allergology treatments, vaccine distribution, immunology products
Industry1 code
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Allergy Immunotherapy Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Immunotherapy Products
TypeOthers
Description

Specialty allergy immunotherapy treatments sold to healthcare providers, pharmacies, and patients. The company focuses on the specialty allergology market with immunotherapy as its flagship offering.

roxall.es
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1RoxVac
Description

Platform enabling pharmacies to register and track vaccine orders in real-time.

roxvac.roxall.com
Core offering1 text field

ROXALL Group is an international specialty pharmaceutical company that develops and distributes prescription allergy immunotherapy treatments (vaccines) for the treatment of allergic conditions. Its products are sold through pharmacies and wholesalers across six European countries, complemented by RoxVac, a proprietary pharmacy-facing platform for real-time order registration and delivery tracking.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ROXALL Group is a specialty pharmaceutical company focused on allergology and immunotherapy. The company operates two main offerings: its core immunotherapy product portfolio for treating allergies, and RoxVac, a pharmacy order management and tracking platform that allows pharmacies to register orders and monitor delivery status in real-time. The company maintains a professional area for healthcare providers alongside its patient-facing services.

Product and service1 record
1ROXALL Allergy Immunotherapy Portfolio
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Global leader in allergy immunotherapy, headquartered in Denmark. Directly competes with ROXALL in prescription allergen-specific immunotherapy for respiratory and venom allergies, serving the same allergologist and pharmacy channels across Europe.

TypeDirect peer
Description

Specialty immunotherapy company focused on allergy diagnosis and treatment, now majority-owned by Bertelli. Competes head-to-head with ROXALL in subcutaneous and sublingual immunotherapy across European markets.

TypeDirect peer
Description

UK-listed specialty pharma developing and commercialising allergy vaccines and diagnostics. Closely comparable product portfolio, therapeutic focus, and European distribution model to ROXALL.

TypeDirect peer
Description

Dutch-German specialty allergen manufacturer producing diagnostic and immunotherapy products. Direct overlap with ROXALL in venoms, pollens, and indoor allergens sold through European pharmacies and allergists.

TypeDirect peer
Description

Spanish-based specialty pharma with deep focus on allergy diagnostics and immunotherapy. Strong overlap with ROXALL's home market (Spain) and therapeutic positioning.

TypeEmerging player
Description

Vienna-based biotech specializing in recombinant allergen immunotherapy and peptide vaccines. Smaller and more pipeline-stage than ROXALL but directly comparable therapeutic category and European footprint.

7Anergis
TypeEmerging player
Description

Swiss clinical-stage company developing synthetic peptide vaccines for birch and other pollen allergies. Comparable therapeutic mechanism and target prescribers but currently pre-commercial versus ROXALL's established portfolio.

TypeEmerging player
Description

French biotech developing epicutaneous immunotherapy patches for food and respiratory allergies. Competes for the same allergologist mindshare and represents a potential modality disruptor to injectable immunotherapy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Roxall Medizin

Specialty Allergy Immunotherapy Pharmaceuticalsroxall.com

ROXALL Group is a private specialty pharmaceutical company developing and distributing prescription allergy immunotherapy treatments across six European countries, serving allergologists, pharmacies, wholesalers, and patients via direct sales and its RoxVac order-tracking platform.

What Roxall Medizin does

ROXALL Group is a privately held specialty pharmaceutical company focused on allergology and immunotherapy, claiming approximately 30 years of innovation in the field (founded circa 1994). The company develops and distributes prescription allergy immunotherapy treatments, positioning immunotherapy as its flagship offering, and serves allergologists, immunology specialists, pharmacies, wholesalers, and patients across six European countries: Spain, Germany, Austria, Italy, Portugal, and Turkey. Its operational headquarters is located in the Zamudio Technology Park in Bizkaia, Spain.

The company's product portfolio is centered on its allergy immunotherapy treatments, with a secondary digital offering in RoxVac—a pharmacy-facing real-time order tracking and management platform launched in 2023 that allows pharmacies and wholesalers to register vaccine orders, monitor delivery status, and access product and batch information. ROXALL also maintains a gated professional area portal for healthcare providers, which includes a portfolio, an events calendar, and a Hymenoptera Blog, alongside a patient-facing section covering allergy education and order tracking.

ROXALL's go-to-market relies on direct sales representatives engaging allergologists and immunology specialists, supported by country-specific localized websites in each European market, professional events and conferences, and distribution through pharmacies and wholesalers. The company emphasizes R&D as part of its identity and has a pharmacovigilance and ethical channel consistent with regulated pharmaceutical operations. No funding rounds, M&A activity, partnerships, or revenue figures are disclosed in the available data.

Roxall Medizin firmographics

Firmographics
Name
Roxall Medizin
Legal name
ROXALL Group
Website
https://roxall.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
101–250 employees
Short description
ROXALL Group is a private specialty pharmaceutical company developing and distributing prescription allergy immunotherapy treatments across six European countries, serving allergologists, pharmacies, wholesalers, and patients via direct sales and its RoxVac order-tracking platform.
Ownership category
akta.pro rank

Roxall Medizin industry classification

Industry
Product category
Specialty Allergy Immunotherapy Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Allergy immunotherapy
  • Specialty pharmaceuticals
  • Allergology treatments
  • Vaccine distribution
  • Immunology products

Where Roxall Medizin is headquartered

Location

Headquarters

HQ city
Oststeinbek
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Roxall Medizin business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Immunotherapy Products: Specialty allergy immunotherapy treatments sold to healthcare providers, pharmacies, and patients. The company focuses on the specialty allergology market with immunotherapy as its flagship offering.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Roxall Medizin product offering

Product offering

Core offering

ROXALL Group is an international specialty pharmaceutical company that develops and distributes prescription allergy immunotherapy treatments (vaccines) for the treatment of allergic conditions. Its products are sold through pharmacies and wholesalers across six European countries, complemented by RoxVac, a proprietary pharmacy-facing platform for real-time order registration and delivery tracking.

Product overview

ROXALL Group is a specialty pharmaceutical company focused on allergology and immunotherapy. The company operates two main offerings: its core immunotherapy product portfolio for treating allergies, and RoxVac, a pharmacy order management and tracking platform that allows pharmacies to register orders and monitor delivery status in real-time. The company maintains a professional area for healthcare providers alongside its patient-facing services.

Differentiator

Problem solved

Functional benefit

Brands

  • RoxVac: Platform enabling pharmacies to register and track vaccine orders in real-time.

Products and services

  • ROXALL Allergy Immunotherapy Portfolio

Companies that use Roxall Medizin

Customer profile

Segments3 records

Ideal customer profiles3 records

Roxall Medizin technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Roxall Medizin partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Roxall Medizin competitors and assessment

Company assessment

Direct peers

  • ALK-Abelló: Global leader in allergy immunotherapy, headquartered in Denmark. Directly competes with ROXALL in prescription allergen-specific immunotherapy for respiratory and venom allergies, serving the same allergologist and pharmacy channels across Europe.
  • Stallergenes Greer: Specialty immunotherapy company focused on allergy diagnosis and treatment, now majority-owned by Bertelli. Competes head-to-head with ROXALL in subcutaneous and sublingual immunotherapy across European markets.
  • Allergy Therapeutics: UK-listed specialty pharma developing and commercialising allergy vaccines and diagnostics. Closely comparable product portfolio, therapeutic focus, and European distribution model to ROXALL.
  • HAL Allergy: Dutch-German specialty allergen manufacturer producing diagnostic and immunotherapy products. Direct overlap with ROXALL in venoms, pollens, and indoor allergens sold through European pharmacies and allergists.
  • Leti Pharma: Spanish-based specialty pharma with deep focus on allergy diagnostics and immunotherapy. Strong overlap with ROXALL's home market (Spain) and therapeutic positioning.

Emerging players

  • Biomay: Vienna-based biotech specializing in recombinant allergen immunotherapy and peptide vaccines. Smaller and more pipeline-stage than ROXALL but directly comparable therapeutic category and European footprint.
  • Anergis: Swiss clinical-stage company developing synthetic peptide vaccines for birch and other pollen allergies. Comparable therapeutic mechanism and target prescribers but currently pre-commercial versus ROXALL's established portfolio.
  • DBV Technologies: French biotech developing epicutaneous immunotherapy patches for food and respiratory allergies. Competes for the same allergologist mindshare and represents a potential modality disruptor to injectable immunotherapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Roxall Medizin social profiles

Digital presence

Roxall Medizin financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Roxall Medizin leadership team

Management profile

Number of profiles

Roxall Medizin subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Roxall Medizin funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Roxall Medizin M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roxall Medizin

What does Roxall Medizin do?

ROXALL Group is an international specialty pharmaceutical company that develops and distributes prescription allergy immunotherapy treatments (vaccines) for the treatment of allergic conditions. Its products are sold through pharmacies and wholesalers across six European countries, complemented by RoxVac, a proprietary pharmacy-facing platform for real-time order registration and delivery tracking.

Is Roxall Medizin a public or private company?

Roxall Medizin is a private company. It is classified as unknown and is currently operating.

When was Roxall Medizin founded?

Roxall Medizin was founded in 1994. It employs 101 to 250 people.

Where is Roxall Medizin based?

Roxall Medizin is headquartered in Oststeinbek, Germany, in the Europe region.

How does Roxall Medizin make money?

One revenue line is on record: immunotherapy Products.

Who are Roxall Medizin's main competitors?

Direct peers on record are ALK-Abelló, Stallergenes Greer, Allergy Therapeutics, HAL Allergy and Leti Pharma. Emerging players are Biomay, Anergis and DBV Technologies.

Does Roxall Medizin have an API?

No public API is recorded for Roxall Medizin.

What industry is Roxall Medizin in?

Roxall Medizin's product category is Specialty Allergy Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales